Clinical trials
for patients
Learn about available clinical trials
-
April 28, 2025Pamplona/MadridIn recruitmentEarly phase
GO44537 Clinical trial to evaluate the safety, pharmacokinetics and activity of RO7656594 in patients with advanced or metastatic prostate cancer.
The objective of this study is to evaluate RO7656594 at different doses to determine if it is safe and how it is processed by your body. The study consists of two parts: a dose-finding stage and a scale-up stage. -
April 28, 2025MadridIn recruitment
MK-2870-022 Phase 3 clinical trial to evaluate the efficacy and safety of maintenance therapy with sacituzumab tirumotecan versus standard therapy in platinum-sensitive recurrent ovarian cancer.
The main objective is to evaluate the safety and tolerability of tirumotecan sacituzumab in maintenance treatment with bevacizumab. -
April 14, 2025PamplonaIn recruitment
OROLEAK Clinical trial for the evaluation of oropharyngeal leak in second- and third-generation laryngeal masks: impact on clinical practice
Our main objective is to measure the pressures occurring in the esophagus and determine whether they are a risk factor for vomiting, by comparing two commercially available laryngeal masks. -
April 9, 2025PamplonaIn recruitment
REGISTRO VASOPRES Ensayo clínico de vasopresina para el shock
The main objective is to characterize the routine clinical practice of vasopressin use in the context of shock in a multicenter observational study. -
April 9, 2025Pamplona/MadridIn recruitmentEarly phase
CYTB323J12201 Trial of rapcabtagene autoleucel vs. reference therapy in patients suffering from systemic lupus erythematosus with active refractory lupus nephritis.
The objective of this study is to find out if rapcabtagene autoleucel (hereafter, YTB323), an investigational new treatment, is safe and effective (if it can help) for people who have systemic lupus erythematosus (SLE) with active lupus nephritis (LN). -
April 9, 2025Pamplona/MadridIn recruitment
BET-PSMA-001 Randomized, multicenter, crossover study of single-patient imaging and dosimetry testing of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetane (Pluvicto®) in patients with metastatic prostate cancer in
This study is being conducted to learn more about injectable rhPSMA-10.1 lutetium (177Lu) (the "study drug") in men with prostate cancer that has progressed during or after prior treatment. -
April 9, 2025Pamplona/MadridIn recruitment
CDX0159-13 Randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of barzolvolimab in patients with chronic spontaneous urticaria who continue to experience symptoms despite treatment with antihistamines.
The purpose of this research study is to test the actual efficacy of barzolvolimab at 2 different dose levels and to determine if it helps people with CSU. Barzolvolimab has been tested in 2 studies of healthy volunteers and 2 studies of patients with CSU. -
March 31, 2025Pamplona/MadridIn recruitment
LOXO-BTK-20030 Clinical trial of pyrtobrutinib (LOXO-305) compared to ibrutinib in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (BRUIN-CLL-314).
The objectives of this clinical trial are as follows: - To determine the response of CLL/LLCP patients to treatment with pyrtobrutinib (group A) compared to ibrutinib (group B). - Determine the duration of beneficial effects of treatment with the study drugs (including how long patients live). - Determine safety and tolerability in group A and group B. - Determine how patients in group A are doing compared to those in group B. -
March 31, 2025PamplonaIn recruitmentEarly phase
81201887MDG3002 Trial for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in primary clinical studies.
The objective of this study is to monitor the safety and occurrence of drug effects over a longer time by following the study patients for 42 months. -
March 31, 2025PamplonaIn recruitment
RMC-6236-302 Phase III, multicenter, open-label, randomized, open-label clinical trial to evaluate RMC-6236 in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDCA).
The purpose of a trial is to collect information about the investigational drug: RMC-6236